MPL Care (MPARK) 3Q25 Financial Results
Tacirler Investment
We evaluate MLP Healthcare’s 3Q25 financial results as neutral. We maintain our 12-month target price of TL 450 per share and our “HOLD” recommendation.
We evaluate MLP Healthcare’s 3Q25 financial results as neutral. We maintain our 12-month target price of TL 450 per share and our “HOLD” recommendation.